Free Trial

Instil Bio (TIL) Competitors

Instil Bio logo
$20.61 -1.01 (-4.67%)
As of 01/3/2025 05:39 PM Eastern

TIL vs. CRMD, RNAC, TKNO, TERN, VERV, MGTX, PRTC, ARCT, ABVX, and ZVRA

Should you be buying Instil Bio stock or one of its competitors? The main competitors of Instil Bio include CorMedix (CRMD), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), Terns Pharmaceuticals (TERN), Verve Therapeutics (VERV), MeiraGTx (MGTX), PureTech Health (PRTC), Arcturus Therapeutics (ARCT), ABIVAX Société Anonyme (ABVX), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.

Instil Bio vs.

Instil Bio (NASDAQ:TIL) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.

Instil Bio has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500.

In the previous week, CorMedix had 3 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for CorMedix and 0 mentions for Instil Bio. CorMedix's average media sentiment score of 1.84 beat Instil Bio's score of 0.00 indicating that CorMedix is being referred to more favorably in the news media.

Company Overall Sentiment
Instil Bio Neutral
CorMedix Very Positive

Instil Bio presently has a consensus target price of $145.00, suggesting a potential upside of 603.54%. CorMedix has a consensus target price of $15.80, suggesting a potential upside of 93.15%. Given Instil Bio's higher possible upside, equities analysts clearly believe Instil Bio is more favorable than CorMedix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Instil Bio
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
CorMedix
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Instil Bio received 76 more outperform votes than CorMedix when rated by MarketBeat users. However, 74.19% of users gave CorMedix an outperform vote while only 50.25% of users gave Instil Bio an outperform vote.

CompanyUnderperformOutperform
Instil BioOutperform Votes
99
50.25%
Underperform Votes
98
49.75%
CorMedixOutperform Votes
23
74.19%
Underperform Votes
8
25.81%

Instil Bio's return on equity of -37.44% beat CorMedix's return on equity.

Company Net Margins Return on Equity Return on Assets
Instil BioN/A -37.44% -25.08%
CorMedix N/A -79.21%-64.68%

CorMedix has higher revenue and earnings than Instil Bio. CorMedix is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Instil BioN/AN/A-$156.09M-$11.56-1.78
CorMedix$12.26M40.48-$46.34M-$0.81-10.10

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 46.5% of Instil Bio shares are owned by insiders. Comparatively, 5.2% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Instil Bio and CorMedix tied by winning 8 of the 16 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TIL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TIL vs. The Competition

MetricInstil BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$134.50M$2.95B$5.21B$9.04B
Dividend YieldN/A1.92%4.99%4.18%
P/E Ratio-1.7846.1687.5317.29
Price / SalesN/A444.141,157.01124.81
Price / CashN/A174.7543.2637.86
Price / Book0.595.855.185.19
Net Income-$156.09M-$41.30M$121.70M$226.98M
7 Day Performance2.79%3.45%3.68%3.14%
1 Month Performance-21.31%3.18%21.78%5.49%
1 Year Performance167.32%15.01%31.65%21.67%

Instil Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TIL
Instil Bio
2.5432 of 5 stars
$20.61
-4.7%
$145.00
+603.5%
+168.4%$134.50MN/A-1.7849
CRMD
CorMedix
2.5305 of 5 stars
$8.10
-1.3%
$15.80
+95.1%
+135.7%$491.48M$12.26M-10.0030Positive News
RNAC
Cartesian Therapeutics
2.7086 of 5 stars
$18.76
-5.2%
$42.86
+128.4%
-12.1%$476.79M$47.94M-0.3637
TKNO
Alpha Teknova
1.0333 of 5 stars
$8.85
+1.4%
$5.00
-43.5%
+129.2%$471.78M$36.35M-11.96240Positive News
Gap Up
TERN
Terns Pharmaceuticals
4.0158 of 5 stars
$5.53
-4.2%
$18.30
+230.9%
-14.2%$469.71M$1M-4.6940
VERV
Verve Therapeutics
2.5628 of 5 stars
$5.54
-8.0%
$25.75
+364.8%
-54.2%$469.04M$24.40M-2.25110News Coverage
MGTX
MeiraGTx
4.1428 of 5 stars
$5.89
-5.2%
$23.50
+299.0%
-5.2%$460.32M$13.93M-4.87300
PRTC
PureTech Health
1.9558 of 5 stars
$18.98
-2.7%
$45.00
+137.1%
-25.8%$454.42M$3.33M0.00100Gap Down
ARCT
Arcturus Therapeutics
2.8621 of 5 stars
$16.64
-2.2%
$66.75
+301.1%
-42.7%$450.73M$142.47M-7.50180Positive News
ABVX
ABIVAX Société Anonyme
2.3657 of 5 stars
$7.05
-1.0%
$38.67
+448.5%
-30.7%$446.60MN/A0.0061Positive News
High Trading Volume
ZVRA
Zevra Therapeutics
2.9414 of 5 stars
$8.21
-2.1%
$21.00
+155.8%
+39.7%$438.22M$24.49M-4.1765Positive News

Related Companies and Tools


This page (NASDAQ:TIL) was last updated on 1/5/2025 by MarketBeat.com Staff
From Our Partners